EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 29, 2021

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients included in the CORIMUNO-19 cohort
• • Patients hospitalized in conventional ward or in the ICU belonging to the following groups: OMS Progression scale 6, 7, 8 AND no acute pulmonary embolism on CT-scan performed in the preceding 72 hours no pulmonary evident bacterial coinfection or superinfection evaluated by non-invasive procedures (serology, antigens, nasopharynx PCR, sputum examination, blood cultures...)
• Exclusion Criteria:
• • Patients in OMS progression class 9
• • Patients with exclusion criteria to the CORIMUNO-19 cohort
• • Pregnancy
• • Active cancer with ongoing treatment
• • acute use of NIV for COPD exacerbation or cardiac decompensation associated to COVID-19
• • Oxygen patient requiring long-term oxygen before hospitalization
• • Patient already included in an interventional research
• • Risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery during the last 3 weeks
• • Hypersensitivity to the active substance (bevacizumab) or to any of the excipients (sucrose, succinic acid, disodium edetate, polysorbate 80, sodium hydroxide, water for injection
• • Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies
• • Persistant uncontrolled arterial hypertension after using to anti-hypertensive drugs
• • Current documented bacterial infection not controlled by antibiotics.
• • Active viral diseases (especially active herpes, chickenpox, shingles),
• • Active tuberculosis or disseminated strongyloidiasis
• • patient with known active hepatitis or with increased level of SGOT or SGPT ≥5N
• • Patient with anormal laboratory results: Absolute neutrophil count (ANC) ≤ 1.0 x 109/L, Platelets (PLT) \< 50 G /L